<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Therapy</journal-id><journal-title-group><journal-title xml:lang="en">Therapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапия</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2412-4036</issn><issn publication-format="electronic">2713-1823</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">288797</article-id><article-id pub-id-type="doi">10.18565/therapy.2022.2.24-31</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RHEUMATOLOGICAL PROBLEMS WITH COVID-19: FROM ARTHRALGIA TO RHEUMATOID ARTHRITIS</article-title><trans-title-group xml:lang="ru"><trans-title>СУСТАВНОЙ СИНДРОМ ПРИ COVID-19: ОТ АРТРАЛГИЙ ДО РЕВМАТОИДНОГО АРТРИТА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>KARATEEV</surname><given-names>Andrey E.</given-names></name><name xml:lang="ru"><surname>КАРАТЕЕВ</surname><given-names>Андрей Евгеньевич</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, head of the Department of inflammatory joint pathology</p></bio><bio xml:lang="ru"><p>д.м.н., начальник отдела воспалительных заболеваний суставов</p></bio><email>aekarat@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">V.A. Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><volume>8</volume><issue>2</issue><issue-title xml:lang="en">VOL 8, NO2 (2022)</issue-title><issue-title xml:lang="ru">ТОМ 8, №2 (2022)</issue-title><fpage>24</fpage><lpage>31</lpage><history><date date-type="received" iso-8601-date="2023-02-26"><day>26</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО «Бионика Медиа»</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2412-4036/article/view/288797">https://journals.eco-vector.com/2412-4036/article/view/288797</self-uri><abstract xml:lang="en"><p>SARS-CoV-2 infection (COVID-19) can cause a systemic inflammatory response, vascular and thrombotic complications, and a wide range of autoimmune disorders. These changes can lead to the development of various rheumatological pathologies. At the onset of the disease, according to series of studies, myalgia is observed in 50,0-84,0%, arthralgia in 13,3-90,0% of patients. After suffering COVID-19, patients could have the situation when joint pain becomes one of the leading manifestations of post-COVID syndrome: on average, it is determined in 15% of cases. Autoimmune reactions associated with SARS-CoV-2 can cause acute post-infectious arthritis, which is characterized mainly by oligoarticular lesions of the joints of the lower extremities, a benign course, and a good «response» to anti-inflammatory therapy. In some cases, COVID-19 acts as a trigger, initiating the development of chronic autoimmune rheumatic diseases, such as systemic vasculitis, systemic lupus erythematosus and rheumatoid arthritis.</p></abstract><trans-abstract xml:lang="ru"><p>Инфекция, вызванная вирусом SARS-CoV-2 (COVID-19), может вызывать системную воспалительную реакцию, сосудистые и тромботические осложнения, широкий спектр аутоиммунных нарушений. Эти изменения могут приводить к развитию различной ревматологической патологии. В дебюте болезни, по данным серии исследований, миалгии отмечаются у 50,0-84,0%, артралгии - у 13,3-90,0% пациентов. После перенесенного COVID-19 боли в суставах становятся одним из ведущих проявлений постковидного синдрома: в среднем они определяются в 15% случаев. Аутоиммунные реакции, связанные с SARS-CoV-2, могут вызывать возникновение острого постинфекционного артрита, который характеризуется преимущественно олигоартрикулярным поражением суставов нижней конечностей, доброкачественным течением, хорошим «ответом» на противовоспалительную терапию. В ряде случаев COVID-19 выступает в роли пускового фактора, инициируя развитие хронических аутоиммунных ревматических заболеваний, таких как системные васкулиты, системная красная волчанка и ревматоидный артрит.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>COVID-19</kwd><kwd>arthralgia</kwd><kwd>postinfectious arthritis</kwd><kwd>rheumatoid arthritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>артралгии</kwd><kwd>постинфекционный артрит</kwd><kwd>ревматоидный артрит</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Marks M., Marks J.L Viral arthritis. Clin Med (Lond). 2016; 16(2): 129-34. https://dx.doi.org/10.7861/clinmedicine.16-2-129.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Krammer F., Smith G.J.D., Fouchier R.A.M. et al. Influenza. Nat Rev Dis Primers. 2018; 4(1): 3. https://dx.doi.org/10.1038/s41572-018-0002-y.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Smatti M., Cyprian F., Nasrallah G. et al. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019; 11(8): 762. https://dx.doi.org/10.3390/v11080762.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Mathew A.J., Ravindran V. Infections and arthritis. Best Pract Res Clin Rheumatol. 2014; 28(6): 935-59. https://dx.doi.org/10.1016/j.berh.2015.04.009.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pathak H., Mohan M.C., Ravindran V. Chikungunya arthritis. Clin Med (Lond). 2019; 19(5): 381-85. https://dx.doi.org/10.7861/clinmed.2019-0035.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Насонов Е.Л. Коронавирусная болезнь - 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021; 1: 5-30. https://dx.doi.org/10.47360/1995-4484-2021-5-30.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Schett G., Manger B., Simon D., Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020; 16(8): 465-70. https://dx.doi.org/10.1038/s41584-020-0451-z.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Liew I.Y., Mak T.M., Cui L. et al. A case of reactive arthritis secondary to coronavirus disease 2019 infection. J Clin Rheumatol. 2020; 26(6): 233. https://dx.doi.org/10.1097/RHU.0000000000001560.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>V'kovski P., Kratzel A., Steiner S. et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021; 19(3): 155-70. https://dx.doi.org/10.1038/s41579-020-00468-6.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sanyal S. How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we know so far. Emerg Top Life Sci. 2020; 4(4): 371-78. https://dx.doi.org/10.1042/ETLS20200165.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Moody R., Wilson K., Flanagan K.L. et al. Adaptive immunity and the risk of autoreactivity in COVID-19.Int J Mol Sci. 2021; 22(16): 8965. https://dx.doi.org/10.3390/ijms22168965.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>To K.K., Tsang O.T., Leung W.S. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020; 20(5): 565-74. https://dx.doi.org/10.1016/S1473-3099(20)30196-1.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Narasaraju T., Tang B.M., Herrmann M. et al. Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19. Front Pharmacol. 2020; 11: 870. https://dx.doi.org/10.3389/fphar.2020.00870.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Peker B.O., Sener A.G., Kaptan Aydogmus F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; Future roadmap for laboratory diagnosis. J Immunol Methods. 2021; 499: 113174. https://dx.doi.org/10.1016/j.jim.2021.113174.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gomes C., Zuniga M., Crotty K.A. et al. Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Sci Alliance. 2021; 4(11): e202101180. https://dx.doi.org/10.26508/lsa.202101180.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhou Y., Han T., Chen J. et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020; 13(6): 1077-86. https://dx.doi.org/10.1111/cts.12805.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Anaya J.-M., Monsalve D.M., Rojas M. et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun. 2021; 4: 100091. https://dx.doi.org/10.1016/j.jtauto.2021.100091.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Seeble J., Waterboer T., Hippchen T. et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2021: ciab611. https://dx.doi.org/10.1093/cid/ciab611.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gracia-Ramos A.E., Martin-Nares E., Hernandez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021; 10(12): 3592. https://dx.doi.org/10.3390/cells10123592.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dotan A., Muller S., Kanduc D. et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021; 20(4): 102792. https://dx.doi.org/10.1016/j.autrev.2021.102792.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Oguz-Akarsu E., Gullu G., Kilic E. et al. Pandemic Study Team. Insight into pain syndromes in acute phase of mild-to-moderate COVID-19: Frequency, clinical characteristics, and associated factors. Eur J Pain. 2022; 26(2): 492-504. https://dx.doi.org/10.1002/ejp.1876.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mustafa S.H., Farooq M.U., Iqbal F. et al. Rheumatological manifestations in patients hospitalized with COVID-19 in a tertiary care setting. J Ayub Med Coll Abbottabad. 2020; 32(Suppl 1)(4):S691-S694.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Knox N., Lee C.S., Moon J.Y., Cohen S.P. Pain manifestations of COVID-19 and their association with mortality: A multicenter prospective observational study. Mayo Clin Proc. 2021; 96(4): 943-51. https://dx.doi.org/10.1016/j.mayocp.2020.12.014.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tuzun S., Keles A., Okutan D. et al. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med. 2021; 57(4): 653-62. https://dx.doi.org/10.23736/S1973-9087.20.06563-6.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Karaarslan F., Guneri F.D., Kardes S. Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022; 41(1): 289-96. https://dx.doi.org/10.1007/s10067-021-05942-x.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Zayet S., Zahra H., Royer P.Y. et al. Post-COVID-19 syndrome: Nine months after SARS-CoV-2 infection in a cohort of 354 patients: Data from the first wave of COVID-19 in Nord Franche-Comte Hospital, France. Microorganisms. 2021; 9(8): 1719. https://dx.doi.org/10.3390/microorganisms9081719.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and metaanalysis. Res Sq. 2021: rs.3.rs-266574. https://dx.doi.org/10.21203/rs.3.rs-266574/v1.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ono K., Kishimoto M., Shimasaki T. et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020; 6(2): e001350. https://dx.doi.org/10.1136/rmdopen-2020-001350.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ouedraogo F., Navara R., Thapa R., Patel K.G. Reactive arthritis Post-SARS-CoV-2. Cureus. 2021; 13(9): e18139. https://dx.doi.org/10.7759/cureus.18139.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Dutta S., Dey S., Poddar A., Pal P. Post-COVID reactive arthritis. Indian J Pediatr. 2022; 89(1):103. https://dx.doi.org/10.1007/s12098-021-03992-2.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Sinaei R., Pezeshki S., Parvaresh S. et al. Post SARS-CoV-2 infection reactive arthritis: a brief report of two pediatric cases. Pediatr Rheumatol Online J. 2021; 19(1): 89. https://dx.doi.org/10.1186/s12969-021-00555-9.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kocyigit B.F., Akyol A. Reactive arthritis after COVID-19: A case-based review. Rheumatol Int. 2021; 41(11): 2031-39. https://dx.doi.org/10.1007/s00296-021-04998-x.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Shimoyama K., Teramoto A., Murahashi Y. et al. Surgically treated reactive arthritis of the ankle after COVID-19 infection: A case report. J Infect Chemother. 2022: S1341-321X(21)00364-0. https://dx.doi.org/10.1016Zj.jiac.2021.12.028.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Мазуров В.И., Беляева И.Б., Саранцева Л.Е. с соавт. Особенности клинического течения ревматических заболеваний у пациентов, перенесших новую коронавирусную инфекцию. Терапия. 2021; 10: 42-54 https://dx.doi.org/10.18565/therapy.2021.10.42-54.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Насонов Е.Л., Белов Б.С., Лила А.М. с соавт. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматиче скими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021; 6: 666-675. https://dx.doi.org/10.47360/1995-4484-2021-666-675.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Raiker R., DeYoung C., Pakhchanian H. et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021; 51(5): 1057-66. https://dx.doi.org/10.1016/j.semarthrit.2021.08.010.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Dewanjee S., Kandimalla R., Kalra R.S. et al. COVID-19 and rheumatoid arthritis crosstalk: Emerging association, therapeutic options and challenges. Cells. 2021; 10(12): 3291. https://dx.doi.org/10.3390/cells10123291.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Perrot L., Hemon M., Busnel J.M. et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021; 3(1): e6-e8. https://dx.doi.org/10.1016/S2665-9913(20)30396-9.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Baimukhamedov C., Barskova T., Matucci-Cerinic M. Arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021; 3(5): e324-e325. https://dx.doi.org/10.1016/S2665-9913(21)00067-9.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Roongta R., Chattopadhyay A., Ghosh A. Correspondence on «Onset of rheumatoid arthritis after COVID-19: Coincidence or connected?». Ann Rheum Dis. 2021 Apr 27: annrheumdis-2021-220479. https://dx.doi.org/10.1136/annrheumdis-2021-220479.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Derksen V.F.A.M., Kissel T., Lamers-Karnebeek F.B.G. et al. Onset of rheumatoid arthritis after COVID-19: Coincidence or connected? Ann Rheum Dis. 2021: annrheumdis-2021-219859. https://dx.doi.org/10.1136/annrheumdis-2021-219859.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Mukarram M.S., Ishaq Ghauri M., Sethar S. et al. COVID-19: An emerging culprit of inflammatory arthritis. Case Rep Rheumatol. 2021; 2021: 6610340. https://dx.doi.org/10.1155/2021/6610340.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Baimukhamedov C., Makhmudov S., Botabekova A. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection.Int J Rheum Dis. 2021; 24(11): 1440-41. https://dx.doi.org/10.1111/1756-185X.14220.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Terracina K.A., Tan F.K. Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol. 2021; 3(7): e469-e470. https://dx.doi.org/10.1016/S2665-9913(21)00108-9.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Коронавирус в мире: данные по странам и регионам. Доступ: https://www.bbc.com/russian/news-51706538 (дата обращения - 11.02.2022). URL: https://www.bbc.com/russian/news-51706538 (date of access - 11.02.2022).</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Martel-Pelletier J., Maheu E., Pelletier J.P. et al. A new decision tree for diagnosis of osteoarthritis in primary care: International consensus of experts. Aging Clin Exp Res. 2019; 31(1): 19-30. https://dx.doi.org/10.1007/s40520-018-1077-8.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Cush J.J. Rheumatoid arthritis: Early diagnosis and treatment. Med Clin North Am. 2021; 105(2): 355-65. https://dx.doi.org/10.1016/j.mcna.2020.10.006.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Yong S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021; 53(10): 737-54. https://dx.doi.org/10.1080/23744235.2021.1924397.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Drozdzal S., Rosik J., Lechowicz K. et al. COVID-19: Pain management in patients with SARS-CoV-2 infection-molecular mechanisms, challenges, and perspectives. Brain Sci. 2020; 10(7): 465. https://dx.doi.org/10.3390/brainsci10070465.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Crook H., Raza S., Nowell J. et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021; 374: n 1648. https://dx.doi.org/10.1136/bmj.n1648.</mixed-citation></ref></ref-list></back></article>
